Medindia
Take charge of your health! Register
Medindia » Health In Focus

3D Skin From Induced Pluripotent Stem Cells To Treat Spinal Birth Defect

by Dr. Lakshmi Venkataraman on June 7, 2017 at 4:36 PM
Listen to this News

Highlights:

Novel 3D skin produced by induced pluripotent stem cells could successfully treat myelomeningocele at 28-29 weeks of gestation, according to a study in Japan's National Research Institute for Child Health and Development, undertaken by senior study author Akihiro Umezawa, and his team.

The Necessity of New Stem Cell Therapies For Myelomeningocele

Usually, babies born with myelomeningocele undergo surgery to repair the defect within the first few days after birth, although the results may not be optimal. Some centers perform intrauterine surgery, which reportedly have a better outcome than post-natal surgery. However, intrauterine surgery is associated with an increased incidence of premature birth and other complications, making it necessary to explore safer and effective alternative prenatal treatments.


To this end, Umezawa and his team set out to develop a minimally invasive technique to produce and transplant artificial skin grafts that could cover large defects earlier in the prenatal period, potentially aiming at better long-term prognosis while at the same time reducing surgical risks.

‘Treatment of myelomeningocele prenatally at 28 weeks using artificial skin, appears a safer and more effective option than current therapies.’

"We provide preclinical proof of concept for a fetal therapy that could improve outcomes and prevent lifelong complications associated with myelomeningocele--one of the most severe birth defects," says senior study author Akihiro Umezawa of Japan's National Research Institute for Child Health and Development. "Since our fetal cell treatment is minimally invasive, it has the potential to become a much-needed novel treatment for myelomeningocele."

Generating 3D Skin using iPSCs To Treat Myelomeningocele

Testing The 3D Artificial Skin On Rats

What Is Myelomeningocele?

Myelomeningocele, the most serious and common form of spina bifida, is a neural tube defect where the bones of the spine are completely formed. Consequently, portions of the spinal cord and nerves come out through the defect. Babies born with this disorder typically have an exposed area or a fluid-filled sac on the mid to lower back. Most children with this condition are at risk of brain damage since excess fluid builds up in their brains. They also suffer from symptoms such as loss of bladder or bowel control, numbness over the legs or feet, weakness and paralysis of the legs.

What Are Pluripotent Stem Cells?

Induced pluripotent stem cells (iPSCs) are produced by genetically reprogramming skin or blood cells. These iPSCs are capable of differentiating into any type of human cell or tissue and have thus become an inexhaustible source of such cells for therapeutic purposes.

The generation and use of iPSCs overcomes the ethical issues surrounding the use of embryonic stem cells for research and treatment purposes.

The use of iPSCs was pioneered by Shinya Yamanaka from Japan, for which he was awarded the Nobel Prize in 2012.

The current study illustrates once again the importance of stem cells and tissue engineering technology in treating several diseases.

Conclusion

Dr Umezawa says, "We are encouraged by our results and believe that our fetal stem cell therapy has great potential to become a novel treatment for myelomeningocele. However, additional studies in larger animals are needed to demonstrate that our fetal stem cell therapy safely promotes long-term skin regeneration and neurological improvement."

References:

  1. Kazuhiro Kajiwara, Tomohiro Tanemoto, Seiji Wada, Jurii Karibe, Norimasa Ihara, Yu Ikemoto, Tomoyuki Kawasaki, Yoshie Oishi, Osamu Samura, Kohji Okamura, Shuji Takada, Hidenori Akutsu, Haruhiko Sago, Aikou Okamoto, Akihiro Umezawa. Fetal Therapy Model of Myelomeningocele with Three-Dimensional Skin Using Amniotic Fluid Cell-Derived Induced Pluripotent Stem Cells. Stem Cell Reports (2017) DOI: http://dx.doi.org/10.1016/j.stemcr.2017.05.0
Source: Medindia

Cite this Article

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Dr. Lakshmi Venkataraman. (2017, June 07). 3D Skin From Induced Pluripotent Stem Cells To Treat Spinal Birth Defect. Medindia. Retrieved on Dec 23, 2024 from https://www.medindia.net/news/healthinfocus/3d-skin-from-induced-pluripotent-stem-cells-to-treat-spinal-birth-defect-170677-1.htm.

  • MLA

    Dr. Lakshmi Venkataraman. "3D Skin From Induced Pluripotent Stem Cells To Treat Spinal Birth Defect". Medindia. Dec 23, 2024. <https://www.medindia.net/news/healthinfocus/3d-skin-from-induced-pluripotent-stem-cells-to-treat-spinal-birth-defect-170677-1.htm>.

  • Chicago

    Dr. Lakshmi Venkataraman. "3D Skin From Induced Pluripotent Stem Cells To Treat Spinal Birth Defect". Medindia. https://www.medindia.net/news/healthinfocus/3d-skin-from-induced-pluripotent-stem-cells-to-treat-spinal-birth-defect-170677-1.htm. (accessed Dec 23, 2024).

  • Harvard

    Dr. Lakshmi Venkataraman. 2017. 3D Skin From Induced Pluripotent Stem Cells To Treat Spinal Birth Defect. Medindia, viewed Dec 23, 2024, https://www.medindia.net/news/healthinfocus/3d-skin-from-induced-pluripotent-stem-cells-to-treat-spinal-birth-defect-170677-1.htm.

View Non AMP Site | Back to top ↑